SITC 2022 | Remaining challenges in reducing or preventing cardiotoxicity in patients receiving immunotherapy

Han Zhu, MD, Stanford University, Standford, CA, discusses remaining challenges in reducing or preventing cardiotoxicity in patients receiving immunotherapy. Fatality rates of myocarditis can be u to 50%, much higher than the mortality rate of patients with classical myocarditis form viral syndromes, so early detection is critical. Prevention may not be attainable, but catching early cases will aid in decreasing rates of mortality. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.